about us

Emerge Health is an Australian Pharmaceutical company focused on delivering high quality medicines to people living with rare diseases. We are committed to addressing unmet clincal needs, by working collaboratively with ethical international partners to ensure the right product, reaches the right patient at the right time.
Emerge Health has a unique, highly experienced team with a successful track record in Australian and New Zealand pharmaceutical markets. Our goal is to provide better therapies for patients, through the development of valuable long-term relationships with clinicians, suppliers and international partners.
Products supplied include those that
- provide safe and effective solutions to critical and emergency care situations;
- medicines that fulfil orphan drug designation, thereby treating rare diseases in the Australia and New Zealand population;
- are considered a low priority for other pharmaceutical companies.
Emerge Health strives to fast track the regulatory approval and reimbursement process where use and adoption is driven by unmet clinical need,
for the most difficult to treat patients.
Mission
Vision
PEOPLE FIRST | We focus on the needs of patients and their healthcare professionals
POWERED WITH PASSION | Believing in everything we do, we can make a difference
PARTNER OF CHOICE | Offering partners a contemporary approach, tailoring our service to their needs in Australia, New Zealand and the Asia Pacific region
PERSONALISED SERVICE | Positive experiences with our customers every time
The Founders of Emerge Health
The Emerge Health management team has over 50 years experience in the Australian Pharmaceutical sector, with vast expertise in new product
registration and launch. This expertise also includes:
- product access and commercialisation (sales and marketing),
- local and international business development, and
- pricing and reimbursement which is particularly important for market access in the very price sensitive Australian market.
Chris Rossidis

Head of Commercial Operations: Chris has proven leadership, developing business strategies within the pharmaceutical, biotech, and medical device sectors.
Chris Rossidis has more than seventeen years of leadership, developing business strategies within the pharmaceutical, biotech, and medical device sectors. His background includes business development/licensing, strategy development and implementation, general management, sales, marketing, full financial control, process and systems improvement as well as governance leadership.
A person of professional standing, integrity and intellectual authority, Chris is a strategic thinker with a decisive leadership style and creative approach to solving business challenges. Significant recent achievements include the restructure of a medium sized ASX listed healthcare company, implementing a comprehensive change management programme, developing a new business model for sustainable future growth. Chris boasts high level commercial competencies, building growth globally in a highly competitive marketplace. Building international licensing and partnership agreements, Chris is an expert client relationship leader leveraging off successes into new markets.
Chris possesses a strong strategic approach to functional issues with excellent operational expertise.
Peter Davey

Head of Pricing and Market Access: Peter has over 20 years experience in price and market access in Australia and internationally, and has a track record in the successful start up and running of new businesses
Peter Davey has extensive experience in pharmaceutical pricing, reimbursement and research based activities involved over the product life cycle. From 1995 to 2005 he co-founded and ran Australia’s largest pricing and reimbursement consultancy, employing 45 staff in offices located in Sydney and London. After it was acquired by IMS Health, Peter was appointed the IMS Principal for Pricing and Market Access for Asia Pacific and Japan.
Through these roles he worked with all the major multinational pharmaceutical companies and consulted through Australasia, Europe, Asia and the Middle East. He has been heavily involved with company teams working on the launch of new products and has worked on over 300 new pharmaceutical products. He has spoken widely at international conferences and has been a member of Australia Government committees overseeing funding and research.
Over the past 3 years he has worked in product licensing and pharmaceutical policy, with a focus on pricing and health services practice.
If you would like to explore partnering opportunities with Emerge Health, please contact us.